Davis_2023_Adv.Pharmacol_97_283

Reference

Title : Cytochrome P450-derived eicosanoids in brain: From basic discovery to clinical translation - Davis_2023_Adv.Pharmacol_97_283
Author(s) : Davis CM , Ibrahim AH , Alkayed NJ
Ref : Advances in Pharmacology , 97 :283 , 2023
Abstract :

Cytochrome P450 metabolism of arachidonic acid produces epoxyeicosatrienoates (EETs) and hydroxyeicosatetraenoates (HETEs). Both classes of eicosanoids play important and opposing roles in brain function and disease. EETs promote vasodilation and exhibit antiinflammatory and cytoprotective properties; their biological action is blunted by metabolism to less active diols by the enzyme soluble epoxide hydrolase (sEH). EETs levels are dysregulated in disease states, primarily due to increased activity of sEH. Inhibition of sEH is a promising therapeutic approach for multiple brain disorders including stroke, dementia, subarachnoid hemorrhage and epilepsy. In this chapter, we summarize evidence implicating P450 eicosanoids and their synthetic and metabolizing enzymes in brain health and disease, and experimental and clinical studies targeting these pathways for brain disorders. We also discuss the diagnostic utility of quantifying P450 eicosanoids and their enzymes as disease biomarkers. Remarkable progress has been achieved in translating basic science discoveries in this field clinically.

PubMedSearch : Davis_2023_Adv.Pharmacol_97_283
PubMedID: 37236762

Related information

Citations formats

Davis CM, Ibrahim AH, Alkayed NJ (2023)
Cytochrome P450-derived eicosanoids in brain: From basic discovery to clinical translation
Advances in Pharmacology 97 :283

Davis CM, Ibrahim AH, Alkayed NJ (2023)
Advances in Pharmacology 97 :283